U.S. FDA grants Orphan Drug Designation to gene therapy for treatment of CLN5 Batten Disease

The therapy is an adeno-associated virus vector with engineered transgene encoding the human CLN5 gene for patients with CLN5 Batten disease, a rare, paediatric-onset and rapidly progressive neurodegenerative disease, with no approved treatment options.


Biospace Inc.